![]() |
|
|
Unidad de Hepatología Experimental, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain
In this study we describe a battery of fluorescence assays for rapid measurement in intact cells of the activity of nine cytochromes P450 (P450s) involved in drug metabolism. The assays are based on the direct incubation of monolayers of cells expressing individual P450 enzymes with a fluorogenic substrate followed by fluorimetric quantification of the product formed and released into incubation medium. For each individual P450 activity, different fluorescence probes were examined, and the one showing the best properties (highest metabolic rates, lowest background fluorescence) was selected: 3-cyano-7-ethoxycoumarin for CYP1A2 and CYP2C19, coumarin for CYP2A6, 7-ethoxy-4-trifluoromethylcoumarin for CYP2B6, dibenzylfluorescein for CYP2C8, 7-methoxy-4-trifluoromethylcoumarin (MFC) for CYP2C9 and CYP2E1, 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin for CYP2D6, and 7-benzyloxy-4-trifluoromethylcoumarin for CYP3A4. Fluorescence-based assays are highly sensitive and allow the simultaneous measurement of a large number of samples using plate readers, thus enhancing sample throughput. Major advantages over high-throughput assays in subcellular fractions are that, as living cells are used, manual handling and enzyme damage are minimized, the endoplasmic reticulum of the cells remains intact, exogenous cofactors or NADPH-regenerating systems are not required, and transport processes are maintained. These assays can be applied to preliminary screening of inhibitory effects of new drugs on individual P450 enzymes. After comparison of the results obtained using the fluorescent probes in intact P450-expressing cells and those obtained using the high-performance liquid chromatography-based selective assays in the same cells, in primary human hepatocytes or in human liver microsomes, a fairly good agreement was found.
This article has been cited by other articles:
![]() |
M. Siller, P. Anzenbacher, E. Anzenbacherova, K. Dolezal, I. Popa, and M. Strnad Interactions of Olomoucine II with Human Liver Microsomal Cytochromes P450 Drug Metab. Dispos., June 1, 2009; 37(6): 1198 - 1202. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Finn, L. A. McLaughlin, S. Ronseaux, I. Rosewell, J. B. Houston, C. J. Henderson, and C. R. Wolf Defining the in Vivo Role for Cytochrome b5 in Cytochrome P450 Function through the Conditional Hepatic Deletion of Microsomal Cytochrome b5 J. Biol. Chem., November 14, 2008; 283(46): 31385 - 31393. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Ehnert, A. K. Nussler, A. Lehmann, and S. Dooley Blood Monocyte-Derived Neohepatocytes as in Vitro Test System for Drug Metabolism Drug Metab. Dispos., September 1, 2008; 36(9): 1922 - 1929. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Jancova, E. Anzenbacherova, B. Papouskova, K. Lemr, P. Luzna, A. Veinlichova, P. Anzenbacher, and V. Simanek Silybin Is Metabolized by Cytochrome P450 2C8 in Vitro Drug Metab. Dispos., November 1, 2007; 35(11): 2035 - 2039. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kumar Identification of a Novel Laser Dye Substrate of Mammalian Cytochromes P450: Application in Rapid Kinetic Analysis, Inhibitor Screening, and Directed Evolution J Biomol Screen, August 1, 2007; 12(5): 677 - 682. [Abstract] [PDF] |
||||
![]() |
S. Sudsakorn, J. Skell, D. A. Williams, T. J. O'Shea, and H. Liu Evaluation of 3-O-Methylfluorescein as a Selective Fluorometric Substrate for CYP2C19 in Human Liver Microsomes Drug Metab. Dispos., June 1, 2007; 35(6): 841 - 847. [Abstract] [Full Text] [PDF] |
||||